US2909462A
(en)
|
1955-12-08 |
1959-10-20 |
Bristol Myers Co |
Acrylic acid polymer laxative compositions
|
US4168062A
(en)
|
1977-12-05 |
1979-09-18 |
Mccarthy Gerald F |
Automated goalie
|
US4258029A
(en)
|
1979-04-23 |
1981-03-24 |
Connaught Laboratories Limited |
Synthetic adjuvants for stimulation of antigenic responses
|
US5155020A
(en)
|
1989-03-08 |
1992-10-13 |
Health Research Inc. |
Recombinant poxvirus host range selection system
|
US5378457A
(en)
|
1981-12-24 |
1995-01-03 |
Virogenetics Corporation |
Interferon sensitive recombinant poxvirus vaccine
|
US5364773A
(en)
|
1991-03-07 |
1994-11-15 |
Virogenetics Corporation |
Genetically engineered vaccine strain
|
US5174993A
(en)
|
1981-12-24 |
1992-12-29 |
Health Research Inc. |
Recombinant avipox virus and immunological use thereof
|
US4722848A
(en)
|
1982-12-08 |
1988-02-02 |
Health Research, Incorporated |
Method for immunizing animals with synthetically modified vaccinia virus
|
US4769330A
(en)
|
1981-12-24 |
1988-09-06 |
Health Research, Incorporated |
Modified vaccinia virus and methods for making and using the same
|
US4603112A
(en)
|
1981-12-24 |
1986-07-29 |
Health Research, Incorporated |
Modified vaccinia virus
|
US5110587A
(en)
|
1981-12-24 |
1992-05-05 |
Health Research, Incorporated |
Immunogenic composition comprising synthetically modified vaccinia virus
|
US5505941A
(en)
|
1981-12-24 |
1996-04-09 |
Health Research, Inc. |
Recombinant avipox virus and method to induce an immune response
|
US5833975A
(en)
|
1989-03-08 |
1998-11-10 |
Virogenetics Corporation |
Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
|
US4436727A
(en)
|
1982-05-26 |
1984-03-13 |
Ribi Immunochem Research, Inc. |
Refined detoxified endotoxin product
|
US4882278A
(en)
|
1983-04-29 |
1989-11-21 |
President And Fellows Of Harvard College |
Non-toxinogenic vibrio cholerae mutants
|
US4945050A
(en)
|
1984-11-13 |
1990-07-31 |
Cornell Research Foundation, Inc. |
Method for transporting substances into living cells and tissues and apparatus therefor
|
NZ214716A
(en)
|
1985-01-07 |
1989-04-26 |
Syntex Inc |
1,2-dialkoxy-omega-trialkylammonium cationic surfactants
|
US4923808A
(en)
|
1985-03-12 |
1990-05-08 |
Genentech, Inc. |
Method for identifying mutants secreting high levels of heterologous proteins
|
DE3521994A1
(de)
|
1985-06-20 |
1987-01-02 |
Bayer Ag |
N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
|
US5141742A
(en)
|
1986-02-07 |
1992-08-25 |
Oncogen |
Vaccines against melanoma
|
US5015580A
(en)
|
1987-07-29 |
1991-05-14 |
Agracetus |
Particle-mediated transformation of soybean plants and lines
|
US5504005A
(en)
|
1987-03-02 |
1996-04-02 |
Albert Einstein College Of Medicine Of Yeshiva University |
Recombinant mycobacterial vaccine
|
EP0347425B1
(en)
|
1987-03-02 |
1995-12-27 |
Whitehead Institute For Biomedical Research |
Recombinant mycobacterial vaccine
|
CA1331443C
(en)
|
1987-05-29 |
1994-08-16 |
Charlotte A. Kensil |
Saponin adjuvant
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
US4956281A
(en)
|
1987-06-03 |
1990-09-11 |
Biogen, Inc. |
DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
|
US6699475B1
(en)
|
1987-09-02 |
2004-03-02 |
Therion Biologics Corporation |
Recombinant pox virus for immunization against tumor-associated antigens
|
CA1341245C
(en)
|
1988-01-12 |
2001-06-05 |
F. Hoffmann-La Roche Ag |
Recombinant vaccinia virus mva
|
US5093258A
(en)
|
1988-08-26 |
1992-03-03 |
Therion Biologics Corporation |
Recombinant fowlpox virus and recombination vector
|
US6780407B1
(en)
|
1989-03-08 |
2004-08-24 |
Aventis Pasteur |
Pox virus comprising DNA sequences encoding CEA and B7 antigen
|
JP3044062B2
(ja)
|
1989-03-08 |
2000-05-22 |
ヘルス・リサーチ・インク |
組換えポックスウイルス宿主選択系
|
US5225336A
(en)
|
1989-03-08 |
1993-07-06 |
Health Research Incorporated |
Recombinant poxvirus host range selection system
|
ES2200016T3
(es)
|
1989-03-21 |
2004-03-01 |
Vical Incorporated |
Expresion de secuencias polinucleotidicas exogenas en un vertebrado.
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
ES2194834T3
(es)
|
1989-06-26 |
2003-12-01 |
Powderject Vaccines Inc |
Transformacion por medio de particulas de celulas somaticas animales.
|
EP0463157A4
(en)
|
1990-01-24 |
1992-06-03 |
Biogen, Inc. |
Lfa-3 as a vaccine adjuvant
|
US5204243A
(en)
|
1990-02-14 |
1993-04-20 |
Health Research Incorporated |
Recombinant poxvirus internal cores
|
JPH05504067A
(ja)
|
1990-02-26 |
1993-07-01 |
コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼイション |
大腸菌及びマイコバクテリアのためのシャトルプラスミド
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
GB9015888D0
(en)
|
1990-07-19 |
1990-09-05 |
Smithkline Biolog |
Vectors
|
EP0468520A3
(en)
|
1990-07-27 |
1992-07-01 |
Mitsui Toatsu Chemicals, Inc. |
Immunostimulatory remedies containing palindromic dna sequences
|
SE9003978D0
(sv)
|
1990-12-13 |
1990-12-13 |
Henrik Garoff |
Dna expressionssystem baserade paa ett virus replikon
|
WO1992011354A1
(en)
|
1990-12-18 |
1992-07-09 |
The General Hospital Corporation |
VIBRIO CHOLERAE STRAINS DEFECTIVE IN irgA EXPRESSION, AND CHOLERA VACCINES DERIVED THEREFROM
|
CA2097931C
(en)
|
1990-12-18 |
2003-07-29 |
Samuel I. Miller, Iii |
Salmonella vaccines
|
US5843456A
(en)
|
1991-03-07 |
1998-12-01 |
Virogenetics Corporation |
Alvac poxvirus-rabies compositions and combination compositions and uses
|
EP0575491B1
(en)
|
1991-03-07 |
2003-08-13 |
Virogenetics Corporation |
Genetically engineered vaccine strain
|
CA2102623C
(en)
|
1991-05-06 |
2003-04-22 |
Jeffrey Schlom |
Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
|
US5541104A
(en)
|
1991-05-23 |
1996-07-30 |
Ludwig Institute For Cancer Research |
Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
|
US5342774A
(en)
|
1991-05-23 |
1994-08-30 |
Ludwig Institute For Cancer Research |
Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
|
US6235525B1
(en)
|
1991-05-23 |
2001-05-22 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
|
AU2185592A
(en)
|
1991-06-06 |
1993-01-08 |
Med Immune, Inc. |
Induction of ctl responses to foreign antigens expressed in mycobacteria
|
US5283185A
(en)
|
1991-08-28 |
1994-02-01 |
University Of Tennessee Research Corporation |
Method for delivering nucleic acids into cells
|
US6037135A
(en)
|
1992-08-07 |
2000-03-14 |
Epimmune Inc. |
Methods for making HLA binding peptides and their uses
|
JP3881689B2
(ja)
|
1992-03-11 |
2007-02-14 |
パウダージェクト ヴァクシンズ,インコーポレイテッド |
免疫不全ウイルス用の遺伝子ワクチン
|
JPH07505283A
(ja)
|
1992-03-20 |
1995-06-15 |
ベイラー・カレッジ・オブ・メディシン |
Dnaトランスポーター系および使用方法
|
EP1236473A3
(en)
|
1992-04-03 |
2003-01-15 |
The Regents Of The University Of California |
Self-assembling polynucleotide delivery system
|
HU219808B
(hu)
|
1992-06-25 |
2001-08-28 |
Smithkline Beecham Biologicals S.A. |
Adjuvánst tartalmazó vakcinakompozíció és eljárás annak előállítására
|
ATE242319T1
(de)
|
1992-07-06 |
2003-06-15 |
Harvard College |
Deletionsmutanten als impfstoffe gegen cholera
|
US5662907A
(en)
*
|
1992-08-07 |
1997-09-02 |
Cytel Corporation |
Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
|
JP3608788B2
(ja)
|
1992-08-31 |
2005-01-12 |
ルドヴィグ・インスティテュート・フォー・キャンサー・リサーチ |
Mage−3遺伝子から誘導されてhla−a1により提示される単離されたノナペプチドおよびそれらの用途
|
US6222012B1
(en)
|
1992-08-31 |
2001-04-24 |
Ludwig Institute For Cancer Research |
Isolated nonapeptides presented by HLA molecules, and uses thereof
|
US5405940A
(en)
|
1992-08-31 |
1995-04-11 |
Ludwig Institute For Cancer Research |
Isolated nonapeptides derived from MAGE genes and uses thereof
|
US5462871A
(en)
|
1992-08-31 |
1995-10-31 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules which encode MAGE derived nonapeptides
|
DK0681483T3
(da)
|
1993-01-26 |
2005-11-21 |
Univ Pennsylvania |
Præparater og fremgangsmåder til administration af genetisk materiale
|
CA2156191A1
(en)
|
1993-02-22 |
1994-09-01 |
Stephen B. Calderwood |
Heterologous antigens in live cell vaccine strains
|
IL108915A0
(en)
|
1993-03-18 |
1994-06-24 |
Merck & Co Inc |
Polynucleotide vaccine against influenza virus
|
DE69405551T3
(de)
|
1993-03-23 |
2005-10-20 |
Smithkline Beecham Biologicals S.A. |
3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
|
TW360548B
(en)
|
1993-04-08 |
1999-06-11 |
Powderject Res Ltd |
Products for therapeutic use
|
SG54115A1
(en)
|
1993-04-27 |
1998-11-16 |
Gerber Scient Products Inc |
Thermal printing apparatus with improved power supply
|
US5919676A
(en)
|
1993-06-24 |
1999-07-06 |
Advec, Inc. |
Adenoviral vector system comprising Cre-loxP recombination
|
US5562909A
(en)
|
1993-07-12 |
1996-10-08 |
Massachusetts Institute Of Technology |
Phosphazene polyelectrolytes as immunoadjuvants
|
EP0708637B1
(en)
|
1993-07-14 |
2004-01-28 |
The Regents of the University of California |
Self-assembling polynucleotide delivery system comprising dendrimer polycations
|
NZ271774A
(en)
|
1993-08-06 |
1998-02-26 |
Cytel Corp |
Immunogenic peptides from the c-terminus of the mage-1 (melanoma) antigen
|
US5830877A
(en)
|
1993-08-26 |
1998-11-03 |
The Regents Of The University Of California |
Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
|
US5985847A
(en)
|
1993-08-26 |
1999-11-16 |
The Regents Of The University Of California |
Devices for administration of naked polynucleotides which encode biologically active peptides
|
US5804566A
(en)
|
1993-08-26 |
1998-09-08 |
The Regents Of The University Of California |
Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
|
US5679647A
(en)
|
1993-08-26 |
1997-10-21 |
The Regents Of The University Of California |
Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
TW442569B
(en)
|
1993-10-25 |
2001-06-23 |
Canji Inc |
Recombinant adenoviral vector
|
GB9326174D0
(en)
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
GB9326253D0
(en)
|
1993-12-23 |
1994-02-23 |
Smithkline Beecham Biolog |
Vaccines
|
JPH07190559A
(ja)
|
1993-12-24 |
1995-07-28 |
Zexel Corp |
積層型熱交換器
|
US5851523A
(en)
|
1994-03-24 |
1998-12-22 |
Ludwig Institute For Cancer Research. |
Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
|
US5686068A
(en)
|
1994-03-24 |
1997-11-11 |
Ludwig Institute For Cancer Research |
Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
|
US5554724A
(en)
|
1994-03-24 |
1996-09-10 |
University Of Leiden |
Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
|
US5585461A
(en)
|
1994-03-24 |
1996-12-17 |
Ludwig Institute For Cancer Research |
Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
|
US5554506A
(en)
|
1994-03-24 |
1996-09-10 |
Ludwig Institute For Cancer Research |
Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
|
US5651981A
(en)
|
1994-03-29 |
1997-07-29 |
Northwestern University |
Cationic phospholipids for transfection
|
SE9401091D0
(sv)
|
1994-03-31 |
1994-03-31 |
Bioption Ab |
Alphavirus cDNA vectors
|
US5874560A
(en)
|
1994-04-22 |
1999-02-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Melanoma antigens and their use in diagnostic and therapeutic methods
|
EP0756604A1
(en)
|
1994-04-22 |
1997-02-05 |
THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services |
Melanoma antigens
|
SE9401709D0
(sv)
|
1994-05-18 |
1994-05-18 |
Mathilda Sjoeberg |
Improved alphavirus vectors for expression of heterologous DNA
|
US5997870A
(en)
|
1994-06-03 |
1999-12-07 |
Ludwig Institute For Cancer Research |
Isolated peptides which bind to HLA-B44 Molecules
|
US6060257A
(en)
|
1994-06-03 |
2000-05-09 |
Ludwig Institute For Cancer Research |
Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
|
US20030072774A1
(en)
|
1994-06-10 |
2003-04-17 |
Diane M. Gajewczyk |
Proteinaceous adjuvants
|
CA2194761C
(en)
|
1994-07-15 |
2006-12-19 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US6019982A
(en)
|
1994-08-26 |
2000-02-01 |
The Administrators Of The Tulane Educational Fund |
Mutant enterotoxin effective as a non-toxic oral adjuvant
|
US5527928A
(en)
|
1994-09-30 |
1996-06-18 |
Nantz; Michael H. |
Cationic transport reagents
|
US6045802A
(en)
|
1994-10-03 |
2000-04-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
|
CA2201592A1
(en)
|
1994-10-03 |
1996-04-18 |
The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services |
Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
|
EP1016418B1
(en)
|
1994-10-03 |
2009-12-30 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Host cell comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
FR2726764B1
(fr)
|
1994-11-14 |
1997-01-31 |
Pasteur Merieux Serums Vacc |
Adjuvant pour composition vaccinale
|
US6001349A
(en)
|
1995-02-22 |
1999-12-14 |
Therion Biologics Corporation |
Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
|
US5707618A
(en)
|
1995-03-24 |
1998-01-13 |
Genzyme Corporation |
Adenovirus vectors for gene therapy
|
EP0843731B1
(en)
|
1995-03-24 |
2008-02-13 |
Genzyme Corporation |
Adenovirus vectors for gene therapy
|
GB9620795D0
(en)
|
1996-10-05 |
1996-11-20 |
Smithkline Beecham Plc |
Vaccines
|
UA56132C2
(uk)
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
|
US5792462A
(en)
|
1995-05-23 |
1998-08-11 |
University Of North Carolina At Chapel Hill |
Alphavirus RNA replicon systems
|
US6127116A
(en)
|
1995-08-29 |
2000-10-03 |
Washington University |
Functional DNA clone for hepatitis C virus (HCV) and uses thereof
|
US6951917B1
(en)
|
1995-09-26 |
2005-10-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
MHC-class II restricted melanoma antigens and their use in therapeutic methods
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
WO1997015597A1
(en)
|
1995-10-25 |
1997-05-01 |
Centocor B.V. |
HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
|
WO1997020575A1
(en)
|
1995-12-08 |
1997-06-12 |
The University Of Alabama At Birmingham Research Foundation |
Targeted adenovirus vectors
|
US6083703A
(en)
|
1996-02-09 |
2000-07-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
|
US5840839A
(en)
|
1996-02-09 |
1998-11-24 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
|
FR2746110B1
(fr)
*
|
1996-03-14 |
1998-04-17 |
|
Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
|
FR2748753B1
(fr)
|
1996-05-20 |
1998-08-14 |
Transgene Sa |
Nouveaux vecteurs adenoviraux pour la therapie genique
|
US20050136066A1
(en)
|
1996-06-12 |
2005-06-23 |
Yajun Guo |
Cellular vaccines and immunotherapeutics and methods for their preparation
|
US6805869B2
(en)
|
1996-06-12 |
2004-10-19 |
Shanghai Cp Guojian Pharmaceutical Co., Ltd. |
Cellular vaccines and immunotherapeutics and methods for their preparation
|
US20040156861A1
(en)
|
1996-07-11 |
2004-08-12 |
Figdor Carl Gustav |
Melanoma associated peptide analogues and vaccines against melanoma
|
CA2261990A1
(en)
|
1996-07-25 |
1998-02-05 |
Therion Biologics Corporation |
Recombinant pox virus for immunization against tumor-associated antigens
|
US6265215B1
(en)
|
1996-09-13 |
2001-07-24 |
Ludwig Institute For Cancer Research |
Isolated peptides which complex with HLA-Cw16 and uses thereof
|
AU729690B2
(en)
|
1996-10-10 |
2001-02-08 |
Henrik Garoff |
Alphavirus-retrovirus vectors
|
ATE292980T1
(de)
|
1996-10-11 |
2005-04-15 |
Univ California |
Immunostimulierende oligonucleotidekonjugate
|
GB9621680D0
(en)
|
1996-10-17 |
1996-12-11 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
WO1998017815A1
(en)
|
1996-10-17 |
1998-04-30 |
Oxford Biomedica (Uk) Limited |
Retroviral vectors
|
US5994132A
(en)
|
1996-10-23 |
1999-11-30 |
University Of Michigan |
Adenovirus vectors
|
KR100620481B1
(ko)
|
1996-10-23 |
2006-09-06 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
개선된 백신
|
US7255862B1
(en)
|
1996-11-14 |
2007-08-14 |
Connaught Technology Corporation |
ALVAC/FIV constructs
|
WO1998029556A1
(en)
|
1996-12-31 |
1998-07-09 |
The Wistar Institute |
Recombinant adenoviral vector expressing antigens associated with colorectal tumors
|
AU735459B2
(en)
|
1997-01-30 |
2001-07-12 |
University Of Virginia Patent Foundation |
Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
|
JP2001513643A
(ja)
|
1997-03-06 |
2001-09-04 |
ウーベルラ、クラウス |
レンチウイルスをベースとするベクター及びベクター系
|
US5990091A
(en)
|
1997-03-12 |
1999-11-23 |
Virogenetics Corporation |
Vectors having enhanced expression, and methods of making and uses thereof
|
AU7158398A
(en)
|
1997-04-17 |
1998-11-11 |
Regents Of The University Of California, The |
Use of lentiviral vectors for antigen presentation in dendritic cells
|
WO1998051810A1
(en)
|
1997-05-13 |
1998-11-19 |
University Of North Carolina At Chapel Hill |
Lentivirus-based gene transfer vectors
|
GB9711990D0
(en)
|
1997-06-11 |
1997-08-06 |
Smithkline Beecham Biolog |
Vaccine
|
AU707186B2
(en)
|
1997-07-01 |
1999-07-01 |
Transgene S.A. |
Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
|
US6977074B2
(en)
|
1997-07-10 |
2005-12-20 |
Mannkind Corporation |
Method of inducing a CTL response
|
AU734180B2
(en)
|
1997-08-29 |
2001-06-07 |
Antigenics Llc |
Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
|
AU4110097A
(en)
|
1997-08-29 |
1999-03-22 |
Sue-May Kang |
Method and apparatus for voluntary motor controlled convalescence
|
GB9718901D0
(en)
|
1997-09-05 |
1997-11-12 |
Smithkline Beecham Biolog |
Vaccine
|
US6291430B1
(en)
*
|
1997-09-12 |
2001-09-18 |
Ludwig Institute For Cancer Research |
Mage-3 peptides presented by HLA class II molecules
|
US5965535A
(en)
|
1997-09-12 |
1999-10-12 |
Ludwig Institute For Cancer Research |
Mage-3 peptides presented by HLA class II molecules
|
WO2000000600A2
(en)
|
1997-09-22 |
2000-01-06 |
Chang Lung Ji |
Lentiviral vectors, comprising modified major donor splice sites and major packaging signals
|
ES2245042T3
(es)
|
1997-09-24 |
2005-12-16 |
The Regents Of The University Of California |
Vectores de lentivirus de no primates y sistemas de empaquetamiento.
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
US6756038B1
(en)
|
1997-10-10 |
2004-06-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
|
AU1087299A
(en)
|
1997-10-14 |
1999-05-03 |
Avant Immunotherapeutics, Inc. |
Non-integrating dna vector of retroviral origin having high-protein expres sion, and secreted immunogenic antigens
|
AU1539499A
(en)
|
1997-11-25 |
1999-06-15 |
Princeton University |
Method for preparing adenovirus vectors, vectors so prepared, and uses thereof
|
WO1999026657A1
(en)
|
1997-11-25 |
1999-06-03 |
Musc Foundation For Research Development |
Inhibitors of nitric oxide synthase
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
KR20010033062A
(ko)
|
1997-12-12 |
2001-04-25 |
루이기 낼다이니 |
렌티바이러스성 벡터의 치료학적 용도
|
JP4768121B2
(ja)
*
|
1998-02-05 |
2011-09-07 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Mageファミリーからの腫瘍関連抗原及びそれらをコードする核酸配列、融合タンパク質の及びワクチン接種のための組成物の調製のための使用
|
MXPA00008352A
(es)
|
1998-02-27 |
2002-10-17 |
Univ Pennsylvania |
Vacunas, composiciones inmunoterapeuticas y metodos para usar las mismas.
|
JP2002506618A
(ja)
|
1998-03-20 |
2002-03-05 |
ジェンザイム・コーポレーション |
腫瘍自己抗原に対する免疫誘導
|
EP1064305B1
(en)
|
1998-03-27 |
2004-09-15 |
The Secretary of State for Defence |
Recombinant virus
|
US6171855B1
(en)
|
1998-05-28 |
2001-01-09 |
The Regents Of The University Of Michigan |
Vectors
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US6693086B1
(en)
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
US6407063B1
(en)
|
1998-10-02 |
2002-06-18 |
Ludwig Institute For Cancer Research |
Tumor antigens and CTL clones isolated by a novel procedure
|
EP1117679B9
(en)
|
1998-10-02 |
2010-07-07 |
Ludwig Institute For Cancer Research |
Tumor antigens and ctl clones isolated by a novel procedure
|
CA2721011A1
(en)
|
1999-10-22 |
2001-05-03 |
Aventis Pasteur Limited |
Modified gp100 and uses thereof
|
EP1246646A2
(en)
|
2000-01-05 |
2002-10-09 |
Aventis Pasteur Limited |
Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
|
US20030113919A1
(en)
|
2001-08-17 |
2003-06-19 |
Aventis Pasteur, Ltd. |
Immunogenic targets for melanoma
|
WO2003080800A2
(en)
|
2002-03-20 |
2003-10-02 |
Aventis Pasteur, Inc. |
Prevention and treatment of disease using angiogenesis-and/or tumor antigens
|